Significant Shareholder Reduces Stake by $1.35M via Charitable Transfer
INAB sits 59% above its 52-week low of $1.17.
Summary
Significant shareholders Malcom and Emily Fairbairn reduced their stake in IN8BIO by transferring 724,637 shares, valued at $1.35 million, to a charitable foundation, bringing their beneficial ownership below 5%.
Key Events · Ownership and Investor Activity · INAB
-
Major Share Disposition
The Malcom and Emily Fairbairn 2010 CRUT transferred 724,637 shares of common stock to a charitable foundation for no consideration.
-
Reduced Beneficial Ownership
This disposition, valued at approximately $1.35 million, caused the Fairbairns to cease being beneficial owners of more than five percent of IN8BIO's common stock, significantly reducing their stake.
-
Context of Financial Distress
This reduction in a significant shareholder's stake comes as IN8BIO faces "going concern" warnings and is actively pursuing capital raises, potentially signaling reduced confidence.
Analysis · INAB · Life Sciences
Malcom and Emily Fairbairn, through their CRUT, transferred 724,637 shares, valued at approximately $1.35 million, to a charitable foundation. This disposition represents a substantial portion of IN8BIO's outstanding shares and results in the Fairbairns ceasing to be beneficial owners of more than five percent of the company's common stock. This reduction in a significant shareholder's stake occurs while the company faces "going concern" warnings and is actively seeking to raise capital, which could be interpreted as a lack of conviction.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INAB was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $1.17 to $5.61. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.